Preventing eye disease is the largest unmet need in ophthalmology. Vision is a person’s most valued sense, yet over 250 million people worldwide suffer from preventable sight loss. Despite billions spent annually on palliative treatment, most care remains focused on late-stage interventions after irreversible damage has occurred. Age-related macular degeneration (AMD) is the largest cause of irreversible vision loss in the developed world.
RPS was founded by Jeffrey K. Luttrull, M.D., a retina specialist, who has spent decades treating AMD patients. His unique clinical experience and proprietary treatment regimen uniquely position RPS to solve the problem of prevention in AMD.
A new approach to treatment delivery is required to meet the vast need and the special demands of long-term preventive care. SAPRA™ is designed to meet that need.
SAPRA™ has not yet been evaluated and approved by the U.S. FDA or regulators for other geographies for commercial sales
.png)
.png)
